Pharvaris Announces Annual Meeting of Shareholders
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), announced its annual general meeting of shareholders on June 29, 2022, at 16:00 CEST (10:00 a.m. EDT).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), announced its annual general meeting of shareholders on June 29, 2022, at 16:00 CEST (10:00 a.m. EDT). Meeting details, including the agenda and relevant documents, will be available in the Investors section of its website and the SEC’s website. Pharvaris aims to provide more effective treatments for all HAE sub-types, leveraging its expertise in rare diseases.
Positive
- Pharvaris is developing novel treatments for hereditary angioedema, a significant unmet medical need.
- The company has strong expertise in rare diseases and HAE, enhancing its market position.
Negative
- None.
Details
News Market Reaction – PHVS
The recorded move for PHVS in the trading session of this news was +1.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced the annual general meeting of shareholders will take place on Wednesday, June 29, 2022, at 16:00 CEST (10:00 a.m. EDT).
All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.
About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
Contact:
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com
+1-617-710-7305
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.